Capturing the human embronic stem cell might change the face of medicine. But to get there, a small band of researchers and biotech firms must endure a federal funding ban and ethical controversy.
He's seen R&D done the old Bell Labs way and in the new, market-driven style. Now research vice president of Bellcore, Lucky thinks broadly and deeply about how ideas get from lab to market.
What Have We Learned About Science and Technology From the Russian Experience?
A Beautiful Mind